This study is for people with a specific type of lung cancer called ALK-positive NSCLC. ALK stands for Anaplastic Lymphoma Kinase, and NSCLC means Non-Small Cell Lung Cancer. Researchers want to see if a new medicine, neladalkib (NVL-655), helps patients more than an existing medicine, alectinib. Both medicines aim to stop cancer from getting worse. The study involves 450 patients split into two groups. Each group will receive one of the medicines.

Key Points:

• The study lasts until researchers determine which medicine works better.
• No previous ALK-targeting drugs are allowed, but certain past treatments are okay.
• Participants must have certain test results, like ALK rearrangement, to join.

Before joining, make sure you’re eligible. You shouldn’t have other major health issues or past surgeries recently. If you have specific allergies or other active cancers, you may not qualify. The study offers a chance to try a new treatment, but consider possible risks and benefits.